Adaptive treatment strategies (ATS) are sequential decision-making processes that enable personalized care by dynamically adjusting treatment decisions in response to evolving patient symptoms. While reinforcement learning (RL) offers a promising approach for optimizing ATS, its conventional online trial-and-error learning mechanism is not permissible in clinical settings due to risks of harm to patients. Offline RL tackles this limitation by learning policies exclusively from historical treatment data, but its performance is often constrained by data scarcity—a pervasive challenge in clinical domains. To overcome this, we propose Treatment Stitching (TreatStitch), a novel data augmentation framework that generates clinically valid treatment trajectories by intelligently stitching segments from existing treatment data. Specifically, TreatStitch identifies similar intermediate patient states across different trajectories and stitches their respective segments. Even when intermediate states are too dissimilar to stitch directly, TreatStitch leverages the Schrödinger bridge method to generate smooth and shortest possible bridging trajectories that connect dissimilar states. By augmenting these synthetic trajectories into the original dataset, offline RL can learn from a more diverse dataset, thereby improving its ability to optimize ATS. Extensive experiments across multiple treatment datasets demonstrate the effectiveness of TreatStitch in enhancing offline RL performance. Furthermore, we provide a theoretical justification showing that TreatStitch maintains clinical validity by avoiding out-of-distribution transitions.

Molecular discovery has attracted significant attention in scientific fields for its ability to generate novel molecules with desirable properties. Although numerous methods have been developed to tackle this problem, most rely on an online setting that requires repeated online evaluation of candidate molecules using the oracle. However, in real-world molecular discovery, the oracle is often represented by wet-lab experiments, making this online setting impractical due to the significant time and resource demands. To fill this gap, we propose the Molecular Stitching (MolStitch) framework, which utilizes a fixed offline dataset to explore and optimize molecules without the need for repeated oracle evaluations. Specifically, MolStitch leverages existing molecules from the offline dataset to generate novel `stitched molecules' that combine their desirable properties. These stitched molecules are then used as training samples to fine-tune the generative model using preference optimization techniques. Experimental results on various offline multi-objective molecular optimization problems validate the effectiveness of MolStitch. The source code is available online.

Major Depressive Disorder (MDD) imposes a substantial burden within the healthcare domain, impacting millions of individuals worldwide. Functional Magnetic Resonance Imaging (fMRI) has emerged as a promising tool for the objective diagnosis of MDD, enabling the investigation of functional connectivity patterns in the brain associated with this disorder. However, most existing methods focus on a single brain atlas, which limits their ability to capture the complex, multi-scale nature of functional brain networks. To address these limitations, we propose a novel multi-atlas fusion method that incorporates early and late fusion in a unified framework. Our method introduces the concept of the holistic Functional Connectivity Network (FCN), which captures both intra-atlas relationships within individual atlases and inter-regional relationships between atlases with different brain parcellation scales. This comprehensive representation enables the identification of potential disease-related patterns associated with MDD in the early stage of our framework. Moreover, by decoding the holistic FCN from various perspectives through multiple spectral Graph Convolutional Neural Networks and fusing their results with decision-level ensembles, we further improve the performance of MDD diagnosis. Our approach is easily implemented with minimal modifications to existing model structures and demonstrates a robust performance across different baseline models. Our method, evaluated on public resting-state fMRI datasets, surpasses the current multi-atlas fusion methods, enhancing the accuracy of MDD diagnosis. The proposed novel multi-atlas fusion framework provides a more reliable MDD diagnostic technique. Experimental results show our approach outperforms both single- and multi-atlas-based methods, demonstrating its effectiveness in advancing MDD diagnosis.

Major Depressive Disorder (MDD) is a pervasive disorder affecting millions of individuals, presenting a significant global health concern. Functional connectivity (FC) derived from resting-state functional Magnetic Resonance Imaging (rs-fMRI) serves as a crucial tool in revealing functional connectivity patterns associated with MDD, playing an essential role in precise diagnosis. However, the limited data availability of FC poses challenges for robust MDD diagnosis. To tackle this, some studies have employed Deep Neural Networks (DNN) architectures to construct Generative Adversarial Networks (GAN) for synthetic FC generation, but this tends to overlook the inherent topology characteristics of FC. To overcome this challenge, we propose a novel Graph Convolutional Networks (GCN)-based Conditional GAN with Class-Aware Discriminator (GC-GAN). GC-GAN utilizes GCN in both the generator and discriminator to capture intricate FC patterns among brain regions, and the class-aware discriminator ensures the diversity and quality of the generated synthetic FC. Additionally, we introduce a topology refinement technique to enhance MDD diagnosis performance by optimizing the topology using the augmented FC dataset. Our framework was evaluated on publicly available rs-fMRI datasets, and the results demonstrate that GC-GAN outperforms existing methods. This indicates the superior potential of GCN in capturing intricate topology characteristics and generating high-fidelity synthetic FC, thus contributing to a more robust MDD diagnosis.